BioSpace News Archive

Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announced that it has initiated the rollout of its Hemanext ONE® RBC Processing and Storage System in Europe.

Ortho Regenerative Technologies Inc. announced that it has changed its corporate name to ChitogenX Inc. to better reflect the Company’s expanded clinical and commercial opportunities, mission, values, and core competencies.

Diadem U.S., Inc. reported that it has been awarded a Small Business Innovation Research direct to Phase ll grant for an expected total of approximately $2.5 million from the National Institute on Aging at the National Institutes of Health.

Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.

Covalon Technologies Ltd. an advanced medical technologies company, is pleased to announce that the Company’s Board of Directors has approved the grant of stock options exercisable for a total of 437,500 common shares to certain of its employees.

Veeva Systems announced that INCOG BioPharma Services implemented Veeva Vault Quality Suite as a foundation for digital excellence across its new 90,000-square-foot manufacturing facility.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, announced that members of its senior management team will participate at two investor conferences in September.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors.

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Aura Biosciences Inc. (NASDAQ: AURA), today announced that Phase 2 data evaluating the safety of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (IL/CM)) will be presented at the ESMO 2022 Congress, being held September 9-13, 2022, in Paris, France.